Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2

[EN]The four receptor tyrosine kinases of the ErbB family play essential roles in several physiological processes and have also been implicated in tumor generation and/or progression. Activation of ErbB1/EGFR is mainly triggered by epidermal growth factor (EGF) and other related ligands, while activ...

ver descrição completa

Detalhes bibliográficos
Autores: Esparís Ogando, Azucena, Díaz Rodríguez, María Elena, Montero, Juan Carlos, Yuste, Laura, Crespo, Piero, Pandiella Alonso, Atanasio
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2002
País:España
Recursos:Universidad de Salamanca (USAL)
Repositorio:GREDOS. Repositorio Institucional de la Universidad de Salamanca
OAI Identifier:oai:gredos.usal.es:10366/167831
Acesso em linha:http://hdl.handle.net/10366/167831
Access Level:acceso abierto
Palavra-chave:Erk5, Breast cancer, signaling, Neuregulin
Breast Neoplasms
Neuregulins
Humans
Cell Division
Antineoplastic Agents
Microscopy
Enzyme Inhibitors
Mitogen-Activated Protein Kinases
Phthalimides
Phosphorylation
MAP Kinase Signaling System
Nitriles
Butadienes
Mitogen-Activated Protein Kinase 7
Recombinant Fusion Proteins
2302 Bioquímica
proteínas de fusión recombinantes
humanos
inhibidores enzimáticos
proteína cinasa activada por mitógenos 7
nitrilos
proteína cinasas activadas por mitógenos
división celular
microscopía
sistema de señalización de las MAP cinasas
antineoplásicos
butadienos
neurregulinas
neoplasias de la mama
fosforilación
ftalimidas
id ES_79a2ddc458130df4e0b9dcc16d30dd3c
oai_identifier_str oai:gredos.usal.es:10366/167831
network_acronym_str ES
network_name_str España
repository_id_str
spelling Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2Esparís Ogando, AzucenaDíaz Rodríguez, María ElenaMontero, Juan CarlosYuste, LauraCrespo, PieroPandiella Alonso, AtanasioErk5, Breast cancer, signaling, NeuregulinBreast NeoplasmsNeuregulinsHumansCell DivisionAntineoplastic AgentsMicroscopyEnzyme InhibitorsMitogen-Activated Protein KinasesPhthalimidesPhosphorylationMAP Kinase Signaling SystemNitrilesButadienesMitogen-Activated Protein Kinase 7Recombinant Fusion Proteins2302 Bioquímicaproteínas de fusión recombinanteshumanosinhibidores enzimáticosproteína cinasa activada por mitógenos 7nitrilosproteína cinasas activadas por mitógenosdivisión celularmicroscopíasistema de señalización de las MAP cinasasantineoplásicosbutadienosneurregulinasneoplasias de la mamafosforilaciónftalimidas[EN]The four receptor tyrosine kinases of the ErbB family play essential roles in several physiological processes and have also been implicated in tumor generation and/or progression. Activation of ErbB1/EGFR is mainly triggered by epidermal growth factor (EGF) and other related ligands, while activation of ErbB2, ErbB3, and ErbB4 receptors occurs by binding to another set of EGF-like ligands termed neuregulins (NRGs). Here we show that the Erk5 mitogen-activated protein kinase (MAPK) pathway participates in NRG signal transduction. In MCF7 cells, NRG activated Erk5 in a time- and dose-dependent fashion. The action of NRG on Erk5 was dependent on the kinase activity of ErbB receptors but was independent of Ras. Expression in MCF7 cells of a dominant negative form of Erk5 resulted in a significant decrease in NRG-induced proliferation of MCF7 cells. Analysis of Erk5 in several human tumor cell lines indicated that a constitutively active form of this kinase was present in the BT474 and SKBR3 cell lines, which also expressed activated forms of ErbB2, ErbB3, and ErbB4. Treatments aimed at decreasing the activity of these receptors caused Erk5 inactivation, indicating that the active form of Erk5 present in BT474 and SKBR3 cells was due to a persistent positive stimulus originating at the ErbB receptors. In BT474 cells expression of the dominant negative form of Erk5 resulted in reduced proliferation, indicating that in these cells Erk5 was also involved in the control of proliferation. Taken together, these results suggest that Erk5 may play a role in the regulation of cell proliferation by NRG receptors and indicate that constitutively active NRG receptors may induce proliferative responses in cancer cells through this MAPK pathway.Taylor & Francis202520252002info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10366/167831reponame:GREDOS. Repositorio Institucional de la Universidad de Salamancainstname:Universidad de Salamanca (USAL)InglésDGES PM97-0061Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:gredos.usal.es:10366/1678312026-06-07T06:28:51Z
dc.title.none.fl_str_mv Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2
title Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2
spellingShingle Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2
Esparís Ogando, Azucena
Erk5, Breast cancer, signaling, Neuregulin
Breast Neoplasms
Neuregulins
Humans
Cell Division
Antineoplastic Agents
Microscopy
Enzyme Inhibitors
Mitogen-Activated Protein Kinases
Phthalimides
Phosphorylation
MAP Kinase Signaling System
Nitriles
Butadienes
Mitogen-Activated Protein Kinase 7
Recombinant Fusion Proteins
2302 Bioquímica
proteínas de fusión recombinantes
humanos
inhibidores enzimáticos
proteína cinasa activada por mitógenos 7
nitrilos
proteína cinasas activadas por mitógenos
división celular
microscopía
sistema de señalización de las MAP cinasas
antineoplásicos
butadienos
neurregulinas
neoplasias de la mama
fosforilación
ftalimidas
title_short Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2
title_full Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2
title_fullStr Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2
title_full_unstemmed Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2
title_sort Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2
dc.creator.none.fl_str_mv Esparís Ogando, Azucena
Díaz Rodríguez, María Elena
Montero, Juan Carlos
Yuste, Laura
Crespo, Piero
Pandiella Alonso, Atanasio
author Esparís Ogando, Azucena
author_facet Esparís Ogando, Azucena
Díaz Rodríguez, María Elena
Montero, Juan Carlos
Yuste, Laura
Crespo, Piero
Pandiella Alonso, Atanasio
author_role author
author2 Díaz Rodríguez, María Elena
Montero, Juan Carlos
Yuste, Laura
Crespo, Piero
Pandiella Alonso, Atanasio
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Erk5, Breast cancer, signaling, Neuregulin
Breast Neoplasms
Neuregulins
Humans
Cell Division
Antineoplastic Agents
Microscopy
Enzyme Inhibitors
Mitogen-Activated Protein Kinases
Phthalimides
Phosphorylation
MAP Kinase Signaling System
Nitriles
Butadienes
Mitogen-Activated Protein Kinase 7
Recombinant Fusion Proteins
2302 Bioquímica
proteínas de fusión recombinantes
humanos
inhibidores enzimáticos
proteína cinasa activada por mitógenos 7
nitrilos
proteína cinasas activadas por mitógenos
división celular
microscopía
sistema de señalización de las MAP cinasas
antineoplásicos
butadienos
neurregulinas
neoplasias de la mama
fosforilación
ftalimidas
topic Erk5, Breast cancer, signaling, Neuregulin
Breast Neoplasms
Neuregulins
Humans
Cell Division
Antineoplastic Agents
Microscopy
Enzyme Inhibitors
Mitogen-Activated Protein Kinases
Phthalimides
Phosphorylation
MAP Kinase Signaling System
Nitriles
Butadienes
Mitogen-Activated Protein Kinase 7
Recombinant Fusion Proteins
2302 Bioquímica
proteínas de fusión recombinantes
humanos
inhibidores enzimáticos
proteína cinasa activada por mitógenos 7
nitrilos
proteína cinasas activadas por mitógenos
división celular
microscopía
sistema de señalización de las MAP cinasas
antineoplásicos
butadienos
neurregulinas
neoplasias de la mama
fosforilación
ftalimidas
description [EN]The four receptor tyrosine kinases of the ErbB family play essential roles in several physiological processes and have also been implicated in tumor generation and/or progression. Activation of ErbB1/EGFR is mainly triggered by epidermal growth factor (EGF) and other related ligands, while activation of ErbB2, ErbB3, and ErbB4 receptors occurs by binding to another set of EGF-like ligands termed neuregulins (NRGs). Here we show that the Erk5 mitogen-activated protein kinase (MAPK) pathway participates in NRG signal transduction. In MCF7 cells, NRG activated Erk5 in a time- and dose-dependent fashion. The action of NRG on Erk5 was dependent on the kinase activity of ErbB receptors but was independent of Ras. Expression in MCF7 cells of a dominant negative form of Erk5 resulted in a significant decrease in NRG-induced proliferation of MCF7 cells. Analysis of Erk5 in several human tumor cell lines indicated that a constitutively active form of this kinase was present in the BT474 and SKBR3 cell lines, which also expressed activated forms of ErbB2, ErbB3, and ErbB4. Treatments aimed at decreasing the activity of these receptors caused Erk5 inactivation, indicating that the active form of Erk5 present in BT474 and SKBR3 cells was due to a persistent positive stimulus originating at the ErbB receptors. In BT474 cells expression of the dominant negative form of Erk5 resulted in reduced proliferation, indicating that in these cells Erk5 was also involved in the control of proliferation. Taken together, these results suggest that Erk5 may play a role in the regulation of cell proliferation by NRG receptors and indicate that constitutively active NRG receptors may induce proliferative responses in cancer cells through this MAPK pathway.
publishDate 2002
dc.date.none.fl_str_mv 2002
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10366/167831
url http://hdl.handle.net/10366/167831
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv DGES PM97-0061
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:GREDOS. Repositorio Institucional de la Universidad de Salamanca
instname:Universidad de Salamanca (USAL)
instname_str Universidad de Salamanca (USAL)
reponame_str GREDOS. Repositorio Institucional de la Universidad de Salamanca
collection GREDOS. Repositorio Institucional de la Universidad de Salamanca
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411364594778112
score 15,81155